Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine versus midazolam as adjuvants to peribulbar block for vitreoretinal surgery
IRCT20201220049777N2Phase 2Completed
- Sponsor
- Research Institute of Ophthalmology
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ketamine and midazolam in vitreoretinal disease (VRD) (3 arms), sponsored by Research Institute of Ophthalmology. Primary endpoints: Onset of globe akinesia and Duration of analgesia. Started Jul 2021; status: completed.
02
Drugs
ketaminemidazolam
03
Conditions
vitreoretinal disease (VRD)
Beyond the preview
Go deeper on IRCT20201220049777N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201220049777N2.